Hunter syndrome (MPS II) presentations will include analysis from continued follow-up of Phase 1/2 data for tividenofusp alfa (DNL310), currently under FDA Priority ReviewPreliminary data from Phase 1 ...

SPR will feature eight abstracts on 60-day peripheral nerve stimulation (PNS) with SPRINT® PNS that will be presented at the ...

Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene therapy candidate for Type ...

Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will ...

AtaiBeckley Inc. (NASDAQ: ATAI) (“AtaiBeckley” or “Company”), a clinical-stage biotechnology company on a mission to transform patient outcomes by developing rapid-acting, durable and convenient ...

Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene therapy candidate for Type ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

(NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced upcoming presentations highlighting ...

Upon abstract acceptance, all posters must be uploaded and recorded on VoiceThread by January 26, 2026 at 5 p.m. All posters that are narrated on VoiceThread by the deadline will be officially listed ...

Charlie Smith. Poster exhibit. Case of Fetal Immature Trauma. The Southern Radiological Conference, Marriott's Grand Hotel, Resort and Spa, Point Clear, Alabama, January 25-27, 2013. Charlie Smith.

Researchers, Extension professionals, students and industry partners are invited to participate in the 2026 North Dakota ...